Wordt geladen...

Response and Resistance to BCR-ABL1-Targeted Therapies

Chronic myeloid leukemia (CML), caused by constitutively active BCR-ABL1 fusion tyrosine kinase, has served as a paradigm for successful application of molecularly targeted cancer therapy. The development of the tyrosine kinase inhibitor (TKI) imatinib allows patients with CML to experience near-nor...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Cancer Cell
Hoofdauteurs: Braun, Theodore P., Eide, Christopher A., Druker, Brian J.
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: 2020
Onderwerpen:
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7722523/
https://ncbi.nlm.nih.gov/pubmed/32289275
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ccell.2020.03.006
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!